Recent submissions
Now showing items 21-40 of 4660
-
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
(ELSEVIER, 2024-03-01)In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the ... -
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.
(ELSEVIER, 2024-03-01)The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently ... -
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.
(Elsevier BV, 2024-05-15)Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a critical stress sentinel that coordinates cell survival, inflammation, and immunogenic cell death (ICD). Although the catalytic function of RIPK1 ... -
Winners vs Losers: The glutamate-NMDAR signalling axis in the regulation of cell fitness
(Institute of Cancer Research (University Of London), 2024-05-21)Cell competition is an evolutionary conserved quality control process that eliminates suboptimal or potentially dangerous cells. For ‘unfit’ cells to be detected, their competitive status needs to be compared to the ... -
Exploring mechanisms of response and resistance to immuno-oncology approaches in melanoma
(Institute of Cancer Research (University Of London), 2024-05-21)Background Immuno-oncology strategies have transformed the prognosis of advanced melanoma; in particular, immune checkpoint inhibitors (ICIs) provide durable response in a subset of patients, while tebentafusp (tebe) is ... -
Tracking tumour evolution through adjuvant therapy in Triple Negative Breast Cancer
(Institute of Cancer Research (University Of London), 2024-05-20)Abstract Relapsed Triple Negative Breast Cancer (TNBC) carries a poor prognosis. Improved understanding of the molecular features of early disease, and the evolution of TNBC from early to relapsed disease, is likely to ... -
Targeting the inflammatory response in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2024-05-20)Prostate cancer is a leading cause of male cancer mortality. Despite inflammation being implicated in prostate cancer initiation and progression, patient outcomes have been minimally impacted by immunotherapies that have ... -
Systems biology of the motif-mediated cell cycle interactome
(Institute of Cancer Research (University Of London), 2024-05-09)The eukaryotic cell cycle is a tightly controlled series of events leading to cell division. It relies on a complex network of regulatory proteins, serving as checkpoints to oversee DNA replication and ensure orderly cell ... -
Utilising Quantitative Imaging And Radiomics To Unravel Intra-tumoural Heterogeneity In Soft Tissue Sarcoma
(Institute of Cancer Research (University Of London), 2024-05-09)Soft tissue sarcomas (STS) are rare mesenchymal tumours that exhibit extensive biological and clinical heterogeneity. Our understanding of this heterogeneity is incomplete and has continued to be a barrier to clinical ... -
Preclinical Modelling of Adenoid Cystic Carcinoma
(Institute of Cancer Research (University Of London), 2024-05-03)Adenoid cystic carcinoma (ACC) lacks accurate preclinical models. Those models that do exist often fail to recapitulate the biology of the disease, lacking expression of the key genetic aberration found in ACC, a MYB::NFIB ... -
Prediction of lymph node metastases using immunohistochemical analysis of primary oral tongue squamous cell carcinomas
(Institute of Cancer Research (University Of London), 2024-04-19)We studied archival tissue samples of oral tongue squamous cell carcinoma (OTSCC) for the expression of genes that have been identified, by cDNA microarray studies and previous studies, to be highly discriminatory for lymph ... -
Advancing magnetic resonance imaging (MRI) guided adaptive radiotherapy techniques for prostate cancer
(Institute of Cancer Research (University Of London), 2024-04-11)Advances in radiotherapy technology have increased precision of treatment delivery, improved cure rates and decreased side effects. The advent of MR-Linacs, which are hybrids of an MRI scanner and linear accelerator, holds ... -
"Why am I still suffering?": Experience of long-term fatigue and neurocognitive changes in oropharyngeal cancer survivors following (chemo)radiotherapy.
(Elsevier BV, 2024-06-01)BACKGROUND: Late effects of cancer treatment, such as neurocognitive deficits and fatigue, can be debilitating. Other than head and neck-specific functional deficits such as impairments in swallowing and speech, little is ... -
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.
(WILEY, 2024-04-01)Recent treatment advancements in multiple myeloma have led to significant improvements in patient outcomes. Maintenance therapy following autologous haematopoietic stem cell transplantation (AHCT) is now standard of care ... -
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
(AMER ASSOC CANCER RESEARCH, 2024-05-15)PURPOSE: Tuvusertib (M1774) is a potent, selective, orally administered ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitor. This first-in-human study (NCT04170153) evaluated safety, tolerability, maximum ... -
DNA-PK controls Apollo's access to leading-end telomeres.
(OXFORD UNIV PRESS, 2024-05-08)The complex formed by Ku70/80 and DNA-PKcs (DNA-PK) promotes the synapsis and the joining of double strand breaks (DSBs) during canonical non-homologous end joining (c-NHEJ). In c-NHEJ during V(D)J recombination, DNA-PK ... -
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.
(SPRINGER, 2024-05-01) -
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.
(AMER ASSOC CANCER RESEARCH, 2024-05-15)PURPOSE: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of predictive biomarkers and concerns over significant ... -
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
(ELSEVIER, 2024-04-01)BACKGROUND: Retifanlimab is a humanized, hinge-stabilized immunoglobulin G4κ monoclonal antibody against human programmed cell death protein 1 (PD-1). This first-in-human, phase I study assessed the safety and efficacy of ... -
Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study
(SPRINGERNATURE, 2024-01-31)<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>The association of fitness with cancer risk is not clear.</jats:p> </jats:sec><jats:sec> ...